


Improving the quality of judgement in cancer therapeutics development

April 1, 2016 to March 31, 2019

Highlights

- Provide cancer researchers with critical tools to improve decision-making surrounding research, development and study design;
- Establish the feasibility of improving researcher judgement in drug development
- Measure the value of improving researcher judgement, minimizing patient burden and maximizing the efficient use of public investments in drug development.



About the project


Therapeutic cancer drug development requires good judgment about product safety, efficacy and the feasibility of trials. However, we know next to nothing about the quality of this judgment. What we do know is that most cancer therapies put into development either fail to show benefit or show unexpected toxicity; that research often takes longer than expected; and that many trials fail to recruit enough patients. We also know that experts in medicine, science and innovation are prone to ignoring conflicting evidence, and overestimating the benefits and feasibility of their projects. Consequently, there is good reason to suspect that expert judgement in the development of cancer therapies could be improved.

Through three subprojects, Dr. Kimmelman's team will directly measure and refine the quality of judgements from a wide array of experts at various critical times in the development process of several types of cancer biotherapeutics. This data will provide BioCanRx with the ability to interpret systematic reviews, and apply better scientific judgement in relation to projects within the network.

Key investigator

Dr. Jonathan **Kimmelman**
 **McGill**

Project investigators




Ottawa
The Ottawa Hospital, University of Ottawa
Scientific investigators
 Dr. Dean Fergusson
 Dr. Manoj Lalu
Collaborators
 Dr. Harry Atkins
 Dr. John Bell
Trainee
 Dr. Marc Avey

Montreal
McGill University
Scientific investigator
 Dr. Jonathan Kimmelman
Trainee
 Daniel Benjamin

Kingston
Canadian Clinical Trials Group
Collaborator
 Dr. Janet Dancey

Toronto
Princess Margaret Cancer Centre, University Health Network
Collaborators
 Dr. Marcus Butler
 Dr. Christopher Paige

Alberta
University of Alberta
Scientific investigator
 Dr. Christopher McCabe



The power to kill cancer lies within us.
 Let's tell our bodies how.

